
A NOVEL c.973G>T MUTATION IN THE ε-SUBUNIT OF THE
ACETYLCHOLINE RECEPTOR CAUSING CONGENITAL
MYASTHENIC SYNDROME IN AN IRANIAN FAMILY Karimzadeh P1,2, Parvizi Omran S3, Ghaedi H4, Omrani MD4,* *Corresponding Author: Mir Davood Omrani, Ph.D., Department of Medical Genetics, Faculty of Medicine,
Shahid Beheshti University of Medical Sciences, Koodakyar Street, Daneshjoo Boulevard, Evin,
Chamran Highway, Tehran, Islamic Republic of Iran, 1985717443. E-mail: davood_omrani@sbmu.ac.ir page: 95
|
RESULTS
Mutation Analysis. Direct sequencing of all 12 exons
of the CHRNE gene, including all intron-exon boundaries,
revealed the plausible presence of a novel missense
mutation in a homozygous state. The mutation was found in exon 11, and substitution of the nucleotide G>T at the
position 973 of the cDNA (c.973G>T) [Figure 2(a)]. This
results in a substitution of valine to leucine amino acid
at position 325 (V325L) of the protein. In addition, the
target sequencing of family members revealed that both
parents carried the same mutation in the heterozygous
state [Figure 2(b)]. This formally confirmed that this patient
likely inherited the mutation from each parent. No
homozygous or heterozygous mutations were detected in
the patient’s siblings.
Pathogenicity of a Novel Mutation. We predicted
the functional consequences of the newly identified mutation
in the CHRNE gene through three in silico prediction
tools. Here, the PolyPhen 2 result revealed that the
c.973 G>T mutation probably damaged the structure and
function of protein with a score of 0.999. According to
the MutationTaster, the V325L mutation was predicted to
be the causal agent for disease. Moreover, SIFT analysis
showed the mutation is deleterious with the score of 0.01.
The variant was not annotated in the National Center for
Biotechnology Information (NCBI), database for single
nucleotide polymorphism (dbSNP) [8], 1000 Genomes
Project [9] Exome Variant Server (http://evs.gs.washing
ton.edu/EVS) and was also not listed in ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar/). Furthermore, the identified
variant was recognized as “likely pathogenic” according
to ACMG/AMP recommendations [10].
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|